Karo Pharma Acquires Nordic OTCs From Teva
Generics giant Teva has divested a portfolio of OTC brands marketed in the Nordics to Sweden's Karo, which has been distributing the products in the region for the past 18 months.
You may also be interested in...
The latest European consumer health business news: France's Mayoly Spindler acquires Italian supplements specialist Biohealth; UK-based Flarin gets funding to expand at home and abroad; and Sweden's Karo plots further M&A in 2021.
Teva reported a substantial loss in the third quarter after registering a goodwill impairment of $4.6bn, largely linked to legal uncertainties as the firm continues to grapple with price-fixing litigation in the US and its pending opioids settlement.
Karo has picked up the full European rights to the Pevaryl antifungal brand from Johnson & Johnson.